The average delay is 11 years between the onset of mental health symptoms and treatment

PGx for Behavioral Health

Providers administering care for behavioral health patients may benefit greatly from the complex medication nuance that can lead to medication adherence issues and successful treatment delays.

The AccessDx PGx Profile:

  • Reduces trial-and-error prescribing
  • Reduces the risk of medication side effects
  • Helps optimize treatment response
  • May help reduce medication changes and delays in symptom relief

Fill out this form to learn more details about PGx use in behavioral health practices.

Name
By filling out this form, you agree to receive communications like newsletters, marketing or promotional materials, and other information from AccessDx Laboratory and our parent company, Aranscia®. You may opt-out of receiving communications from us by using the unsubscribe link at the bottom of all emails or contacting us directly.

PGx testing can help get patients on the right drug faster – shortening the time to successful treatment

PGx-guided medication selection has shown 2.52-fold improved chance of MDD remission
PGx-guided medication selection reduced medication costs over one year by $1035
99% of people have greater than or equal to one PGx variant that may affect their response to medications

Testing Offerings:

PGx Profile – Comprehensive Panel

Includes 37+ high-evidence and emerging-evidence genes, with four add-on genes available (APOE and HLA risk alleles)

PGx Profile – Focused Panel

Includes 20 high-evidence genes with actionable guidance, including HLA risk alleles

PGx Testing May Impact Treatment using:

1st Generation Antipsychotics (Typicals)
2nd Generation Antipsychotics (Atypicals)
3rd Generation Antipsychotics (Atypicals)
ADHD Agents: Non-Stimulants
ADHD Agents: Stimulants

Antidepressants: Atypical Antidepressants
Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs)
Antidepressants: Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Antidepressants: Tricyclic (TCAs) & Tetracyclic Antidepressants
Opiod Use Disorder Drugs

  1. Wang PS, et al. Delays in initial treatment contact after first onset of a mental disorder. Health services research. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1361014/.
    Published April 2004. Accessed October 24, 2024.
  2. Singh AB. Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report. Clin Psychopharmacol Neurosci.
    2015;13(2):150-156. doi:10.9758/cpn.2015.13.2.150
  3. Winner JG, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res
    Opin. 2015;31(9):1633-43. doi: 10.1185/03007995.2015.1063483
  4. Chanfreau-Coffinier C, et al. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users. JAMA Netw Open. 2019;2(6):e195345.